2-Azanorbornyl Alcohols: Very Efficient Ligands for Ruthenium-Catalyzed Asymmetric Transfer Hydrogenation of Aromatic Ketones
作者:Diego A. Alonso、Sofia J. M. Nordin、Peter Roth、Tibor Tarnai、Pher G. Andersson、Marc Thommen、Ulrich Pittelkow
DOI:10.1021/jo991914a
日期:2000.5.1
2-Azanorbornyl-derived amino alcohols were prepared and evaluated as ligands in the Ru(II)-catalyzed asymmetric transfer hydrogenation of aromatic ketones. To improve selectivity and rate, the structure of the ligand was optimized. Acetophenone was reduced using 0.5 mol % catalyst in 40 min in 94% ee. This system was also able to reduce a wide range of aromatic ketones to the corresponding alcohols, while maintaining
[EN] KRAS G12C INHIBITORS<br/>[FR] INHIBITEURS DE KRAS G12C
申请人:MIRATI THERAPEUTICS INC
公开号:WO2020146613A1
公开(公告)日:2020-07-16
The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
(1S, 3R, 4R)-2-Azanorbornyl-3-methanol oxazaborolidines in the asymmetric reduction of ketones
作者:Pedro Pinho、David Guijarro、Pher G. Andersson
DOI:10.1016/s0040-4020(98)00424-4
日期:1998.7
Synthesis of new rigid (1S, 3R, 4R)-2-azanorbornyl-3-methanols and its application in the asymmetric borane reduction of ketones are described. The influence of temperature, solvent and concentration on the reaction outcome were also studied and enantiomeric excess up to 89% could be obtained. (C) 1998 Elsevier Science Ltd. All rights reserved.
KRAS G12C INHIBITORS
申请人:Mirati Therapeutics, Inc.
公开号:US20200331911A1
公开(公告)日:2020-10-22
The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.